Abstract: TMEM16A is essential for Ca 2+ -activated Cl À conductance in vascular smooth muscle. The importance of TMEM16A for agonist-induced vascular constriction and blood pressure control is, however, under debate. Previous studies suggested that TMEM16A might have a complex cellular function beyond being essential for the Ca 2+ -activated Cl À conductance, for example modulation of Ca 2+ channel expression. Mice with constitutive, smooth muscle-specific expression of siRNA directed against Tmem16a (transgenic mice, TG) were generated. Isometric constrictions of isolated aorta, mesenteric, femoral and tail arteries from TG mice were compared with wild-types. Protein expression was analysed by Western blots. Blood pressure and heart rate were studied telemetrically. Significant TMEM16A down-regulation was seen in aorta and tail arteries, while no changes were detected in mesenteric and femoral arteries. Contractile responses of mesenteric and femoral arteries from TG and wild-type mice were not different. Aorta from TG mice showed reduced agonist-induced constriction, while their responses to elevated K + were unchanged. Tail arteries from TG mice also constricted less to adrenergic stimulation than wild-types. Surprisingly, tail arteries from TG mice constricted less to elevated K + too and were more sensitive to nifedipine-induced relaxation. Consistently, TMEM16A down-regulation in tail arteries was associated with reduction in CACNA1C protein (i.e. vascular L-type Ca 2+ channel) expression. No differences in blood pressure and heart rate between the groups were seen. This study suggests a complex contribution of TMEM16A in vascular function. We suggest that TMEM16A modulates arterial contractility, at least in part, indirectly via regulation of CACNA1C expression. 
Chloride ions (Cl À ) are actively accumulated in vascular smooth muscle cells and have an equilibrium potential positive to the resting membrane potential [1] [2] [3] [4] [5] . Activation of Cl À channels, therefore, leads to efflux of Cl À and smooth muscle cell depolarization. Several Cl À channels have been suggested in vascular smooth muscle cells including voltage-gated, Ca 2+ -activated, volume-sensitive Cl À channels and even CFTR [6] .
Of these channel families, the Ca 2+ -activated Cl À channels (CaCCs) have been suggested to play the most important role in agonist-induced constriction [7] . Two protein families, bestrophin [8] [9] [10] and TMEM16 [11] [12] [13] [14] , have been suggested to be CaCC proteins. Multiple bestrophin isoforms [15, 16] and TMEM16A [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] are expressed in human and rodent vascular smooth muscles. Both CaCC families are important for synchronized rhythmic constrictions, but only TMEM16A is essential for sustained constriction of the arterial wall [15, 28] . This suggests that these proteins are associated with different functions in vascular smooth muscle cells [5] .
Several contractile agonists have been shown to induce Ca 2+ -activated Cl À current in smooth muscle cells, suggesting an activation of CaCCs [29] [30] [31] [32] . This Cl À current has been suggested to contribute to membrane depolarization and consequently increases in intracellular Ca 2+ . Thus, agonist-induced Ca 2+ release and/or Ca 2+ influx leads to CaCC-dependent membrane depolarization that opens voltage-gated L-type Ca 2+ channels and further amplifies the intracellular Ca 2+ increase [2, [4] [5] [6] . Previous evidence for the importance of CaCCs in agonistinduced vascular constriction is mostly based on experiments with CaCC inhibitors, for example niflumic acid, IAA-94 and DIDS [33] [34] [35] [36] [37] [38] . However, interpretation of these results is complicated by unspecific effects of these inhibitors [39] . Moreover, Cl À substitution experiments also do not give consistent results. Thus, several studies have shown that acute replacement of extracellular Cl À with non-permeable anions (i.e.
elevation of driving force for Cl À efflux) can potentiate agonist-induced depolarization and constriction [40] [41] [42] , while other publications report only minor effects on membrane potential [43] and constriction [44] . Importantly, these reports differ in vascular beds being studied. Aorta [40] , cerebral arteries [41] , perfused hindquarter [42] circulations and mesenteric arteries have been studied [43, 44] and, in the instance of mesenteric small arteries, reported to have a low sensitivity to Cl À substitution. This suggests a variable significance of Cl However, our previous study demonstrated that these compounds relax rodent small mesenteric arteries even when the transmembrane Cl À gradient is abolished, suggesting a poor selectivity for TMEM16A [11] . Thus, the effect of these drugs should be interpreted with caution, although low concentrations (1 lM) of MONNA were shown to inhibit only the Cl À -dependent component of agonist-induced constriction of rat mesenteric small arteries [11] , suggesting a reasonable specificity.
The role of the Cl À conductance for vascular constriction has also been addressed through modification of TMEM16A expression. Studies where TMEM16A expression was strongly reduced have supported TMEM16A as important for arterial constriction. Thus, arterial constriction was suppressed by siRNA-induced down-regulation of TMEM16A in single cerebral and mesenteric arteries from rats in vitro and in vivo [22, 28] . In addition, smooth muscle-specific knockout of TMEM16A in mice was associated with reduced resting blood pressure and diminished responses to pro-hypertensive treatment [19] . In contrast to siRNA-induced down-regulation in single rat arteries [22, 28] , the smooth muscle-specific TMEM16A knockout mouse did not show reduced arterial contractility of medium-sized and small arteries, for example mesenteric arteries [19] . This was therefore associated with an unchanged expression level of TMEM16A protein in these arteries, which was also low in the corresponding wild-type arteries [19] . However, the knockout mice were characterized by a significant reduction in TMEM16A expression in smooth muscles from aorta and other conduit arteries as well as in precapillary arterioles, which have strong TMEM16A expression [19] . It is suggested that the blood pressure reduction observed in the knockout mice is a result of reduced TMEM16A expression in precapillary arterioles. Other studies have demonstrated an important vascular role of TMEM16A in rodent models of pulmonary and systemic hypertension: these studies reported blood pressure elevation associated with an increase in the expression of TMEM16A in smooth muscle cells from medium-sized arteries [23, 34, 49] . TMEM16A interacts with cytoskeleton proteins [50] as well as with proteins important for Ca 2+ signalling, for example with IP 3 receptors in sensory neurons [51] . Studies in rat cerebral arteries show an interaction of TMEM16A with the storeoperated Ca 2+ channel, TRPC6 [52, 53] . Several studies have
shown an interaction with voltage-gated Ca 2+ channels in retina [54] , in smooth muscle cells of the anal sphincter [55] and in cardiomyocytes [56] . Consistent with this, we demonstrated an interaction between TMEM16A and CACNA1C (i.e. a-subunit of the vascular voltage-gated L-type Ca 2+ channel) proteins at the functional and expressional levels in smooth muscle cells from rat mesenteric small arteries [28] . On this background, we found it of interest to investigate whether chronic, smooth muscle-specific down-regulation of TMEM16A based on a siRNA approach supports the possibility that TMEM16A expression is important for expression of CACNA1C. It has been suggested that the interaction with the Ca 2+ transport proteins provides Ca 2+ for activation of CaCC.
Thus, the functional contribution of TMEM16A to smooth muscle constriction may in part be determined by TMEM16A-dependent modulation of the Ca 2+ sources responsible for elevation of intracellular Ca 2+ [3] .
Due to the plethora of disparate results reported with Cl À substitution, inhibitors of Cl À conductance and gene modification, there is still a need to assess the role of Cl À channels with new models. In this study, we utilized a novel mouse strain, which has smooth muscle-specific siRNA-mediated knockdown of the TMEM16A gene product, to further elaborate upon the role of TMEM16A protein in the contractile response of arteries from different vascular beds, for haemodynamic parameters in vivo, and the potential interaction between TMEM16A and CACNA1C proteins. We hypothesised that TMEM16A down-regulation in these mice would suppress arterial contractility, affect L-type Ca 2+ channel expression and reduce blood pressure, and aimed to test this hypothesis.
Methods
All experiments were approved by and conducted with permission from the Animal Experiments Inspectorate of the Danish Ministry of Food, Agriculture and Fisheries.
DNA construct. The construct for microinjection was composed in a vector already containing the microRNA recognizing site, together with an EGFP coding sequence and a rabbit beta-globin poly A signal ( Figure S1 ). A specific oligonucleotide fragment encoding a Tmem16a-specific siRNA (Table S1 ) was inserted into a vector spanned by a mir30 fragment to generate a short RNA hairpin when expressed in vivo. The structure of endogenous miRNA precursors allows the short hairpin RNA to enter the miRNA pathway and thereby be processed by Dicer into 21 nucleotides siRNA. The SM22a promoter was generated by PCR with primer overhangs containing restriction sites (Table S1 ) from the mouse genome. The amplified SM22a promoter fragment and the vector were cleaved by restriction enzymes ClaI and BamHI. The digested fragments were ligated using T4 ligase into the vector (Fermentas, Thermo Fisher Scientific, Roskilde, Denmark) and transformed into E. coli for cloning. Thus, the SM22a promoter replaced the original CMV promoter. The construct in the vector was sequenced (Europhins MWG, Ebersberg, Germany) to control for mutations that might have occurred during the cloning process. The full construct contained the DNA fusion fragment; SM22a promotereGFP -Tmem16a siRNA -b-globin poly A, and was used for the following transfection into A7r5 cells.
Cell culture expression. Cultured aorta smooth muscle cells, A7r5, were cultured in DMEM (In Vitro, Fredensborg, Denmark) supplemented with 10% foetal calf serum, 1% L-glutamine and 0.1% KPS [kanamycin 2 g, penicillin 1 9 10 6 IU, streptomycin 1 g in 20 mL phosphate-buffered salt solution (PBS)]. Cells were maintained by subcultivation every 4-5 days.
The vectors containing the EGFP siRNA constructs under control of the SM22a promoter ( Figure S1 ) were transfected into A7r5 using Trans-LT1 reagent (Mirus Bio, Madison, USA) according to the manufacturer's protocol. Control transfection was performed as a mock transfection using equal reagent but without DNA vector. The cells were analysed for efficiency of transfection by confirming plasmid expression 72-hr post-transfection ( Figure S2 ). Plasmid expression of GFP was detected by confocal microscopy (LSM-5 Pascal, Zeiss, Jena, Germany; excitation/emission wavelength at 488/530 nm).
Reverse transcription-quantitative polymerase chain reaction (RTqPCR). A7r5 cells positive for GFP were lysed in RLT buffer (Qiagen, Aarhus, Denmark), and RNA was extracted using RNeasy Mini Kit (Qiagen) according to the manufacturer's protocol. The RNA isolation from arteries was carried out with Qiagen Micro Kit (Qiagen). Isolated arterial segments were disrupted in Tissue Lyser (Qiagen). The samples were treated with proteinase K (1 mg/mL, 20 min., 37°C) (Invitrogen, Naerum, Denmark) after homogenization. RNA was converted to cDNA by standard reverse transcription using the transcriptase superscript RTII (Invitrogen) and the RNAse inhibitor SUPERase (Invitrogen).
The level of Tmem16a expression was quantified by hydrolysis probe (TaqMan)-based PCR in accordance with the MIQE Guidelines [57] . All primers were designed to span exon-exon boundaries (Applied Biosystems, Thermo Fisher Scientific, Roskilde, Denmark) (Table S1 ). Probes were covalently attached to 5 0 fluorophore (6-carboxyfluorescein; FAM) and a 3 0 -quencher (tetramethylrhodamine: TAMRA) and localized between forward and reverse primers. Difference in quantification cycles (DC q ) was used to normalize Tmem16a C q value according to reference gene C q value, Gapdh. The expression was calculated as a fold of averaged DC q for parotid glands from wild-type mice [DC q (reference)]. Relative expression:
In some experiments, two reference genes, Gapdh and transferrin receptor (Tfrc), were used. DC q between these two genes was not different between genotypes or transfections, suggesting that their expression was not affected by the interventions.
Generation of a mouse with constitutive Tmem16a siRNA expression. The linearized DNA fragment containing a sequence corresponding to Tmem16a siRNA directed against exon 22 (siRNA2) was microinjected into the male pronuclei of C57BL/6J x DBA/2J F2 oocytes. The two cell stage embryos were afterwards transferred into the infundibulum of pseudopregnant mice 0.5-day post-coitum.
DNA was extracted from tail tip biopsies by digestion with proteinase K (Sigma-Aldrich, Brøndby, Denmark) in Lairds lysis buffer (in mM: 100 Tris-HCl pH 8.5, 5 EDTA, 200 NaCl, 0.5 w/v % SDS), followed by isopropanol (Sigma-Aldrich) extraction [58] . Mice bearing the insertion (transgenic mice, TG) were identified using primers designed to span a part of the GFP fragment (Table S1 ). Amplified fragments were analysed ( Figure S2A ) according to size on 2% agarose gel with an appropriate DNA size marker (100 bp; Invitrogen).
Genomic DNA was digested with HindIII, and the product was separated by agarose gel electrophoresis. DNA fragments were denaturated to single-stranded DNA by alkaline transfer to nitrocellulose membrane. The membrane was blotted with a radioactive labelled probe. This probe was constructed from GFP fragment of the vector construct and labelled with [a-32 P]dCTP. Founder mice with a confirmed insertion of the fusion construct were in mixed strain C57BL/6J 9 DBA/2J background ( Figure S3B and C). The founder mice were mated with C57BL/6J
Bom/Tac and offspring with a single transgene integration backcrossed to this strain for 10 generations.
Isometric myograph experiments. Only 8-to 12-week-old male mice were used in the study. Mice were killed by cervical dislocation and dissected for tissue isolation. Arteries of interest (aorta, mesenteric, femoral and tail arteries) were cleaned of fat and connective tissue, and 2-mm segments were mounted in an isometric wire myograph (DMT, Aarhus, Denmark) as described previously [59] . Both dissection and mounting were carried out in ice-cold PSS. All experiments were performed at 37°C and pH of 7.4 in physiological saline solution (PSS) under continuous aeration with 21% O 2 and 5% CO 2 . Arteries were normalized by stretching to a diameter producing an equivalent transmural pressure of 13.3 kPa (IC100), following reduction in stretch to produce 0.9ÁIC100 [59] . After mounting in the myograph and normalization, arteries were allowed to equilibrate for 30 min. Force development was recorded using LabChart5 and LabChart8 with a PowerLab/8S and 4/25 data acquisition system (ADInstruments, New Zealand). Arterial viability was examined by three separate stimulations with 10 lM noradrenaline (NA). Concentration-response relationships were investigated by cumulative addition of 0.01-30 lM NA or 0.3-300 lM methoxamine or 0.15-15 nM arginine vasopressin (AVP) to the bath solution. The cumulative concentration-response curves to K + -induced depolarization (10, 20, 30, 50 , 80, 124 mM) were obtained in the presence of 1 lM of the ɑ-adrenergic receptor antagonist phentolamine to exclude the contribution of NA released from perivascular adrenergic nerves. Functional contribution of the L-type Ca 2+ channels was tested by preconstriction of arteries with 80 mM K + in the presence of phentolamine followed by relaxation with 0.01-1000 nM nifedipine [60] .
Western blotting. Arteries were dissected as described above and snap-frozen in liquid N 2 . Samples were stored at À80°C for later use. Samples were lysed in ice-cold lysis buffer (Pierce, Thermo Fischer Scientific, Roskilde, Denmark) containing 25 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% NP-40, 5% glycerol and Halt Protease Inhibitor Cocktail (1:100; Thermo Scientific) using a pellet pestle (Sigma-Aldrich). The homogenate was sonicated for 45 sec and then centrifuged at 13,000 rpm for 10 min. The supernatant was collected. Protein quantification in the supernatant was carried out using bicinchoninic acid (BCA) Protein Assay Kit (Pierce, Thermo Fisher Scientific).
Twenty microgram protein from each sample was diluted with 49 Laemmli sample buffer (Bio-Rad, Solna, Sweden) and 50 mM dithiothreitol (DTT) to make a 19 sample buffer. Buffered samples were denatured at 70°C for 10 min. Gels (4-12% Bis-Tris, Bio-Rad) were loaded with a total of 25 lL sample, and separation was performed by electrophoresis followed by transfer onto polyvinylidenfluorid (PVDF) membranes (Merck Millipore, Hellerup, Denmark). PVDF membranes were blocked for 2 hr in Tris-buffered saline (TBS; in mM: 50 Tris, 150 NaCl, pH 7.6) with 0.1% Tween (TBS-T) 5% non-fat dry milk (Blotting-Grade, Bio-Rad) for TMEM16A and CACNA1C protein detection or with 5% BSA (bovine serum albumin; Sigma-Aldrich) for pan-actin detection.
Membranes were divided at approximately 75 kDa, where the upper part was used to identify either TMEM16A or CACNA1C proteins, and the lower part was stained for loading control (pan-actin). Membranes were incubated overnight at 4°C in blocking buffer with primary antibody either against TMEM16A (1:500; Abcam #ab53212, Cambridge, UK) or CACNA1C [1:100; Alomone #ACC-003, Jerusalem, Israel; preincubation with control antigen abolished bands at~190 and~210 kDa (not shown)] or pan-actin (1:1000; Cell Signalling Technology #4968, Leiden, The Netherlands), or glyceraldehyde-3-phosphate dehydrogenase (GAPDH; 1:5000; Cell Signalling Technology #5174). The next day, membranes were washed in TBS-T and incubated with horseradish peroxidase-conjugated secondary goat anti-rabbit (GAR) antibody (1:2000, Cell Signalling Technology #7074) for 2 hr at room temperature. After washings in TBS-T, protein was detected using a chemiluminescent imaging system, ImageQuant LAS 4000 (GE Healthcare Life Sciences, Brøndby, Denmark).
The amount of protein of interest detected with Western blot was quantified using ImageJ (v1.48, NIH, Bethesda, Maryland, USA). The intensity of the band of interest (TMEM16A or CACNA1C protein) was normalized to the reference protein (pan-actin or, in some preliminary experiments, GAPDH) band intensity from the same load. The normalized intensities were expressed as percentage of averaged normalized intensity for wild-type group and compared between tissues from transgenic and wild-type mice.
Blood pressure measurements. Blood pressure was measured using radiotelemetry as described previously [61] . Mice were anaesthetized by a combination of ketamine (60 mg/kg) and xylazine (10 mg/kg) and placed on a thermostatically controlled warming platform to maintain body temperature at 37°C. A midline incision through the shaved skin on the neck was made, and the mandibular glands were separated to access the carotid artery. The catheter of a HD-X11 radiotelemetry transmitter (Data Sciences International, New Brighton, MN, USA) was placed into the carotid artery, and the transmitter body was placed into subcutaneous pocket. The skin incision was closed using 6-0 non-absorbable suture, and a painkiller (0.2 mL/kg; Temgesic; Schering-Plough Europe) was injected subcutaneously at the end of operation.
Mice were allowed to recover for 1 week before measurements were started. A continuous 48-hr registration was made. Telemetry signals were recorded for 10 sec each minute and the data averaged over two recorded hours; from 23:00 to 01:00, from 05:00 to 07:00, from 11:00 to 13:00 and from 17:00 to 19:00 for measurements labelled as 24, 6, 12 and 18, respectively. At the end of the experiment, the mice were challenged by a single bolus injection of phenylephrine (5 mg/kg, i.p.) and blood pressure recorded for 1 hr after injection. Registration was performed with Dataquest A.R.T software 4.3. Analyses were performed with Ponemah analyses software 5.00 (all Data Sciences International) and Microsoft Excel 2010.
Solutions and chemicals. All chemicals were obtained from SigmaAldrich unless otherwise specified. PSS used for myograph experiments and microdissection had the following composition (in mM): 10 HEPES, 119 NaCl, 4. Data analysis. All data are presented as means AE standard error of the mean (S.E.M.). p < 0.05 is considered statistically significant, and n refers to the number of Petri dishes in cell culture studies and to the number of mice in all other experiments. Data were analysed using GraphPad Prism 7. A stable plateau of force in myograph recordings (mN) was converted to wall tension (N/m) by dividing force with two times the arterial segment length (mm) and the cumulative concentration-responses were used to create the averaged concentration-response curves (CRC). CRC were fitted to experimental data with the following formula:
) where X is [agonist] (in log M), Y is the tension response, Top refers to maximum wall tension (F max ), Bottom refers to initial wall tension, and the Hill Slope is variable. From these curves, logEC 50 (the concentration required to constrict the vessel to half-maximal tone) or logIC 50 (the concentration required to relax the vessel by 50%) and F max were derived and compared using an extra sum-of-squares F-test. Two-way ANOVA and t-test for repeatable or non-repeatable measurements were used as appropriate.
Results
Generation and validation of a mouse model. A construct, which successfully passed an efficiency test in A7r5 cells, was used for microinjection. In accordance with the designed structure, transfection of A7r5 cells with the vector containing the SM22a promoter resulted in GFP expression ( Figure S2A ) and down-regulation of Tmem16a expression in comparison with non-transfected cells (Figure S2B) . The expression of Tmem16a was unchanged in mock-transfected cells compared to non-transfected cells. These experiments show that the construct is expressed and that the siRNA can be processed leading to down-regulation of Tmem16a. After pronuclear microinjection, transgenic offspring positive for the GFP transgene were analysed by Southern blot to identify mice with a single insertion ( Figure S3 ). The transgene was crossed back to C57Bl/6J for a minimum of 10 generations.
TMEM16A knockdown reduced agonist-induced constriction of aorta without affecting K + -induced constriction.
Selected single transgene integration was associated with smooth muscle-specific suppression of Tmem16a mRNA ( fig. 1) . A significant reduction in Tmem16a mRNA was seen in aorta and tail arteries from mice with transgene containing integration, while no changes in mesenteric small arteries and femoral arteries were seen. Moreover, the expression of Tmem16a mRNA was unchanged in parotid gland, an epithelial tissue with high expression of Tmem16a [12, 62, 63] . The expression level of Tmem16a in parotid gland was similar to the expression level in aorta ( fig. 1 ). The expression level of Tmem16a in wild-type tail arteries was 7.2 AE 1.3% (n = 8), in femoral arteries 5.4 AE 2.0% (n = 9) and in mesenteric small arteries 2.1 AE 0.5% (n = 20) of the level in the parotid gland. In accordance with the reduced mRNA, we detected significantly reduced TMEM16A protein expression in aorta ( fig. 2A ) and tail arteries ( fig. 3A ) from transgenic mice compared to wild-type. No significant change in TMEM16A protein was seen in mesenteric small arteries ( fig. 4A ) or femoral arteries ( fig. 5A ).
The normalized diameter between arteries from transgenic and wild-type mice was similar (Table S2) . Isometric tension development in response to contractile stimuli was compared for isolated arteries from transgenic and matching wild-type mice. Mouse aorta showed a biphasic, bell-shaped concentration-response curve to NA ( Figure S4A) . A single stimulation with 10 lM NA did not reveal any difference between aorta from different groups (1.03 AE 0.11 N/m (n = 17) and 0.89 AE 0.10 mN/mm (n = 16) for wild-type and transgene aorta, respectively). The concentration-dependent reduction in wall tension at high NA concentrations was partially prevented by pre-incubation with propranolol ( Figure S4B ), suggesting involvement of b-adrenoceptors. In further support of this, the a 1 -adrenoceptorspecific agonist methoxamine did not cause any reduction in wall tension at high agonist concentrations ( Figure S4C ).
The overall constriction response to increasing NA concentrations in the aorta was significantly different between transgenic and wild-type mice ( fig. 2C ). No significant difference in the sensitivities of aorta to NA was found (Table S3) , although the maximal contractile response was significantly smaller in aorta from transgenic mice in comparison with wild-type (Table S4) . Pre-incubation with MONNA (1 lM) [11, 45] , a purported inhibitor for the Ca 2+ -activated Cl À channel, suppressed the NA contractile response in wild-type aorta without significantly altering the transgenic aorta response ( Figure S5A ). In the presence of MONNA, there was no significant difference between the two mouse groups in the NA-induced constrictions of aorta. Constriction of aorta from transgenic mice to AVP was also reduced in comparison with wild-type (fig. 2D) ; no significant difference in EC 50 (Table S3 ) but a reduction maximal constriction was found (Table S4) . When aorta was depolarized with increasing concentrations of K + in the bath solution, no difference in contractile responses between the groups was found ( fig. 2E ; Tables S3 and S4 ). Consistently, expression of the CACNA1C protein (the a-subunit of vascular L-type Ca 2+ channel) was not changed in aorta from transgenic mice in comparison with wild-type ( fig. 2B) . Additionally, the relaxation of aorta preconstricted with K + to increasing concentrations of nifedipine was similar for both transgenic and wild-type mice ( Figure S6A ).
TMEM16A knockdown and suppressed contractility in tail arteries are associated with reduced expression of L-type Ca 2+ channels.
Constriction to both NA ( fig. 3C ) and AVP ( fig. 3D ) was also reduced for tail arteries from transgenic mice in comparison with wild-type. This was due to significantly reduced sensitivity of tail arteries from transgenic mice to agonist in comparison with wild-type (Table S3 ). The maximal response to NA was also reduced in tail arteries from transgenic mice (Table S4) . MONNA suppressed the constriction of tail arteries and repealed the difference between wild-type and transgenic groups ( Figure S5B) . Surprisingly, in contrast to aorta, tail arteries from transgenic mice had reduced constriction to K + -induced depolarization in comparison with wild-type ( fig. 3E ). This was due to reduced maximal contractile response of tail arteries from transgenic mice cf. wild-type to K + elevation (Table S4) , while the sensitivity to K + was unchanged (Table S3) .
We have previously shown that acute down-regulation of TMEM16A in rat small arteries leads to reduced contractile response, at least in part, due to reduced expression of CACNA1C protein [28] . The reduced constriction in response to K + -induced depolarization of tail arteries from transgenic mice in this study suggests similar changes. Consistent with reduced response to the K + depolarization ( fig. 3E ), we found a significant reduction in CACNA1C protein expression in tail arteries from transgenic mice in comparison with wild-type ( fig. 3B ). The reduced functional significance of L-type Ca 2+ channels was further supported by an increased sensitivity to nifedipine of K + -pre-constricted tail arteries from transgenic mice in comparison with wildtype ( Figure S6B ).
No functional and expressional changes in small mesenteric and femoral arteries. In contrast to aorta and tail arteries, mesenteric small arteries and femoral arteries from transgenic mice did not show any significant changes in Tmem16a mRNA level ( fig. 1 ) and TMEM16A protein expression (figs 4A and 5A) in comparison with wild-type. Consistently, we did not observe any significant difference in the contractile responses to NA, AVP and elevation of K + for mesenteric small ( fig. 4C-E ) and femoral arteries ( fig. 5C-E) . Expression of CACNA1C protein was also not different between transgenic and wild-type mice (figs 4B and 5B).
Constitutive down-regulation of TMEM16A in smooth muscles did not affect blood pressure.
Telemetry recordings of blood pressure and heart rate in transgenic and wild-type mice were performed over 48 hr ( fig. 6 ). No significant difference between transgenic and wild-type mice was seen for arterial pressure ( fig. 6A and B) or for heart rates ( fig. 6C ). We challenged mouse blood pressure by a single injection of phenylephrine (5 mg/kg), but no difference in blood pressure responses was seen; an elevation from resting blood pressure to the peak of blood pressure raise was from 96 AE 2 mmHg to 141 AE 5 mmHg for transgenic mice (n = 4) and from 95 AE 2 mmHg to 139 AE 3 mmHg wild-type mice (n = 5).
Discussion
This study provides novel evidence for a complex role of TMEM16A in vascular tissues and supports the suggestion that TMEM16A may be of importance for L-type Ca 2+ channel expression. In our mice, constitutive, smooth muscle-specific expression of siRNA directed against Tmem16a under Fig. 1 . Relative expression of Tmem16a mRNA in parotid gland (n = 10-15) and in different blood vessels, that is aorta (n = 12-15), tail arteries (n = 8-12), femoral arteries (n = 9-10) and mesenteric small arteries (n = 20-21) from transgenic mice in comparison with wild-type controls. The expression was normalized with the reference to averaged expression level in parotid gland from wild-type mice. * and *** indicate p < 0.05 and p < 0.001, respectively.
control of the SM22a promoter significantly down-regulated TMEM16A only in arteries that showed a high level of TMEM16A expression. Smaller arteries with low TMEM16A expression were not significantly affected in transgenic mice. Importantly, in the tail artery, but not in aorta, TMEM16A down-regulation was associated with a reduction in the expression of CACNA1C, that is L-type Ca 2+ channel protein and, accordingly, a suppression of the contractile responses to agonist stimulation and K + -induced depolarization, and an increased sensitivity to nifedipine-induced relaxation.
Differential down-regulation of TMEM16A in different vascular beds. We found that constitutive expression of TMEM16A-specific siRNA under control of the SM22a promoter resulted in a non-uniform down-regulation of TMEM16A. Our initial test with transfection of cultured smooth muscle A7r5 cells with the plasmid containing the Tmem16a siRNA demonstrated the efficiency of the smooth muscle SM22a promoter. Accordingly, in our mouse model, the expression of Tmem16a was not changed in the parotid gland, an epithelial tissue previously characterized to have high expression of TMEM16A [12, 62, 63] . Altogether, these results suggest that the variable down-regulation of TMEM16A in different vascular beds of the transgenic mice may be due to variable expression of the siRNA or different efficiency of the siRNA in different vascular beds. It has to be considered that, in contrast to the conventional Cre-dependent knockout models [19] , the SM22a promoter in this study is controlling the production of siRNA that has only transient effect on the target gene expression Fig. 2 . Aorta from transgenic mice (TG) showed reduced expression of TMEM16A and suppressed agonist-induced constriction in comparison with wild-type (WT) control. Semiquantitative Western blot analyses for TMEM16A (n = 15-16) and for CACNA1C (n = 10-11) protein expressions are shown in panels A and B, respectively. Upper panels show representative Western blot for TMEM16A, CACNA1C and loading control (pan-actin) as indicated. Membranes were cut at approximately 75 kDa, and upper part of the membrane was used to stain with either TMEM16A or CACNA1C antibodies, while lower part of the membrane was stained with pan-actin antibody, respectively. Lower panels show averaged results from Western blot experiments where intensity of the protein of interest (TMEM16A or CACNA1C) band was normalized to reference protein (pan-actin) intensity from the same load and expressed as percentage of averaged normalized level of TMEM16A or CACNA1C in wild-type group. * indicates p < 0.05 (unpaired t-test). Concentration-response curves for NA (panel C; n = 15-16), AVP (panel D; n = 7) and K + -induced depolarization (panel E; n = 7) for aorta's from TG and WT mice. ** indicates p < 0.01, respectively (F-test). [64] . Temporary changes in SM22a promoter activity, for example age-related activity, could therefore lead to corresponding temporary changes in siRNA efficiency [65] . In all, this suggests a disadvantage of this mouse model over the tissue-specific knockout mice [19] , where there is no need for constitutive expression of siRNA over time and modification of the target gene is permanent.
Moreover, variable responses in different vascular beds could be a result of the expressional level of Tmem16a, where low expression level suppressed the efficiency of specific siRNA. Accordingly, we have found a gradient of Tmem16a expression from aorta down to small arteries, where mesenteric and femoral arteries showed low Tmem16a expression while aorta demonstrated relatively high expression level of Tmem16a. This is consistent with previous reports on mouse [19] and rat [26] arterial expression of TMEM16A and our previous reports on Ca 2+ -activated Cl À currents in smooth muscle cells from different vascular beds [66] . How the expressional level may affect the efficiency of siRNA is unclear, but it might be a result of different turnover time.
TMEM16A down-regulation reduces arterial constriction, at least in part, due to reduced expression of L-type Ca 2+ channels. Activation of CaCCs is proposed to be a key step in agonistinduced constriction of vascular smooth muscle cells [1] [2] [3] [4] [5] [6] [7] . This hypothesis is based on the depolarizing action of Ca 2+ -activated Cl À current potentiating a voltage-dependent Ca 2+ influx, which would further stimulate the CaCCs. It has been shown that acute siRNA-induced down-regulation of CaCC protein TMEM16A and pharmacological inhibition of TMEM16A suppress arterial constriction [20, 22, 28] . Our experiments with aorta support this hypothesis by showing that agonist-induced constriction is significantly suppressed by down-regulation of TMEM16A protein, while it is without effect on the constriction induced by K + depolarization. Stronger suppression of agonist-induced constriction in wild-type than in transgenic aorta by MONNA [11] , which abolished the difference between the groups, further supports this hypothesis. Moreover, in accordance with unchanged expression of TMEM16A in mesenteric and femoral arteries, there was no difference between transgenic and control mice in constrictions induced by NA, AVP and K + depolarization.
In accordance with the depolarizing effect of CaCCs [1] [2] [3] [4] [5] [6] [7] , we also found that the TMEM16A-down-regulated tail arteries have a reduced constriction in response to agonist stimulation, that is NA and AVP. Low concentration of MONNA [11] suppressed agonist-induced constriction of tail arteries from wild-type more than from transgenic mice, supporting the down-regulation of TMEM16A in tail arteries. Importantly, if the role of CaCCs for constriction is mediated via the membrane potential, suppression of CaCCs should not affect the contractile response to K + -induced depolarization [5, 11] . However, down-regulation of TMEM16A in tail arteries was associated with reduced constriction in response to K + -induced depolarization. This suggests that the reduced contractility of tail arteries down-regulated for TMEM16A cannot be explained solely by the role of CaCCs for membrane potential. We have previously shown that reduced contractility of TMEM16A-down-regulated arteries can, at least in part, be explained by reduced voltage-dependent Ca 2+ influx because of reduced CACNA1C expression [28] . Consistent with this, a reduced expression of CACNA1C protein was found in this study in tail arteries down-regulated for TMEM16A, while no association between TMEM16A and CACNA1C protein expression was seen for aorta. This was further supported by our functional data, where arteries pre-constricted with K + -induced depolarization were relaxed with increasing concentrations of nifedipine [60] . These nifedipine-induced relaxations were similar for wild-type and transgenic aorta, suggesting similar functional contribution of the L-type Ca 2+ channels. In contrast, we found a reduced functional contribution of the Ltype Ca 2+ channels in tail arteries from transgenic mice compared to arteries from wild-type, which is consistent with the reduction in CACNA1C protein expression. The reason for this is unclear but could be a result of different Ca 2+ dynamics. Thus, agonist-induced constriction in aorta is shown to depend strongly on voltage-dependent Ca 2+ influx, while peripheral artery smooth muscles depend on both Ca 2+ influx and release from intracellular stores [67] . Changes in intracellular Ca 2+ signalling are known to affect gene expression and smooth muscle cell phenotypes [68] via Ca 2+ -sensitive transcription factors [69] [70] [71] , and this can shift smooth muscle cells towards a non-contractile phenotype associated with reduced expression of voltage-gated Ca 2+ channels [72] .
Moreover, it cannot be excluded that TMEM16A acts as a multifunctional protein forming the CaCC as well as being an important intracellular regulator of other functions [5] . Thus, in analogy with CACNA1C protein [73, 74] , TMEM16A or a fragment of TMEM16A may directly modulate gene expression. In fact, TMEM16A was shown to promote the expression of myocardin, a vascular smooth muscle cell marker gene, leading to cell differentiation while inhibiting cell proliferation [17] . Thus, down-regulation of TMEM16A might lead to loss of the contractile phenotype and reduced CACNA1C expression via the myocardin/serum response factor pathway. The significance of these regulatory pathways may differ in aorta and tail arteries [75] . Further research into the interaction between TMEM16A and CACNA1C expression is needed.
Differentiated down-regulation of TMEM16A is not sufficient to affect resting blood pressure. Several previous studies indicated the importance of TMEM16A for blood pressure regulation, but the precise role is still controversial. Thus, TMEM16A is strongly up-regulated in pulmonary [23, 34] and primary [49] hypertension but reduced in secondary systemic hypertension [21] . We have not found any significant difference in blood pressure and heart rate during our 48-hr telemetric recordings from transgenic and wild-type mice. This is in accordance with the lack of differences in passive lumen diameter and contractility of mesenteric and femoral arteries. We suggest that the lack of TMEM16A down-regulation in small, resistance, arteries of our mice is responsible for the lack of effect on blood pressure.
Conclusion
The present study demonstrates that the functional significance of membrane proteins cannot be studied in a single experimental model. Different experimental models should be applied to comprehensively analyse the functional significance of TMEM16A. The current and previous studies [17, 28, 54] suggest that TMEM16A is more than a simple CaCC-forming protein and might serve other cellular functions including regulation of gene expression. This study suggests that the role of TMEM16A for agonist-induced arterial constriction [1] [2] [3] [4] [5] [6] [7] includes regulation of the expression of CACNA1C subunit of the L-type Ca 2+ channels although this relationship may vary between different vascular beds. Fig. 6 . Telemetric registration of blood pressure and heart rate from transgenic (TG) and wild-type (WT) mice over a 48-hr period. Panel A shows mean arterial pressure, panel B systolic and diastolic pressures, and panel C heart rate. Repeated two-way ANOVA did not identify any significant difference between genotypes; circadian rhythm was similar for TG and WT mice (p < 0.001; n = 4 -6).
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